Filing Flows › BeOne Medicines (ONC) › Q3 2026 › vs Q3 2025
BeOne Medicines (ONC) Q3 2026 vs Q3 2025 (year over year)
BeOne Medicines's revenue rose $478M (+34%) from $1.4B in Q3 2025 to $1.9B in Q3 2026. The biggest changes: Product revenue, net +$466M (+34%); BAITUOWEI +$10.9M (+97%); POBEVCY +$218K (+2%). Gross margin 88.5% against 86.1% (+2.4 pts).
BeOne Medicines, Q3 2026: revenue $1.9B (+34% year over year), operating margin 22.2%, net earnings $385M, operating cash flow $509M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 88.5% | 86.1% | +2.4 pts |
| Operating margin | 22.2% | 11.5% | +10.6 pts |
| Net margin | 20.4% | 8.8% | +11.5 pts |
| Free cash flow margin | 25.1% | 25.1% | -0.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| BRUKINSA | $1.4B | $1.0B | $350M | +34% |
| TEVIMBRA | $243M | $191M | $52.7M | +28% |
| XGEVA | $105M | $84.2M | $21.2M | +25% |
| BLINCYTO | $38.9M | $30.5M | $8.4M | +28% |
| Other Revenue | $34.8M | $17.3M | $17.5M | +101% |
| Other | $29.8M | $8.9M | $20.9M | +236% |
| KYPROLIS | $13.9M | $18.4M | −$4.5M | -24% |
| Product revenue, net | $1.9B | $1.4B | $466M | +34% |
| BAITUOWEI | $22.1M | $11.2M | $10.9M | +97% |
| POBEVCY | $10.7M | $10.5M | $218K | +2% |
| Revenue | $1.9B | $1.4B | $478M | +34% |
| Gross profit | $1.7B | $1.2B | $457M | +38% |
| Cost of revenue | $217M | $197M | $20.4M | +10% |
| Operating profit | $419M | $163M | $256M | +157% |
| Operating expenses | $1.3B | $1.1B | $202M | +19% |
| Pre-tax earnings | $410M | $147M | $263M | +179% |
| Other expense, net | $8.3M | $15.9M | −$7.6M | -48% |
| Research & development | $661M | $524M | $137M | +26% |
| SG&A | $593M | $529M | $64.5M | +12% |
| Net earnings | $385M | $125M | $260M | +208% |
| Income tax | $25.7M | $22.3M | $3.3M | +15% |
| Depreciation & amortization | $60.9M | $37.3M | $23.6M | +63% |
| Share-based compensation | $132M | $141M | −$8.3M | -6% |
| Working capital & other | $69.4M | −$99.6M | $169M | — |
| Operating cash flow | $509M | $403M | $106M | +26% |
| Free cash flow (OCF − capex) | $474M | $354M | $119M | +34% |
| Capital expenditures | $35.2M | $48.1M | −$12.9M | -27% |
Questions
How much did BeOne Medicines's revenue grow year over year in Q3 2026?
BeOne Medicines's revenue rose $478M (+34%) from $1.4B in Q3 2025 to $1.9B in Q3 2026.
What drove BeOne Medicines's revenue change in Q3 2026?
Product revenue, net +$466M (+34%); BAITUOWEI +$10.9M (+97%); POBEVCY +$218K (+2%).